|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/00 | |
| C07K 16/22 | |||
| A61K 39/395 | |||
| A61P 13/08 | |||
| A61P 13/10 |
| (11) | Patento numeris | 2291403 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09762162.7 |
| Europos patento paraiškos padavimo data | 2009-06-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-03-09 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-11-15 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2009/052535 |
| Data | 2009-06-15 |
| (87) | Numeris | WO 2009/150635 |
| Data | 2009-12-17 |
| (30) | Numeris | Data | Šalis |
| 61141 P | 2008-06-13 | US |
| (72) |
SHELTON, David, Louis, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | TREATMENT OF CHRONIC PROSTATITIS |
| TREATMENT OF CHRONIC PROSTATITIS |